glp-1 substance use disorder IUPHAR review – Glucagon-like peptide-1 (GLP-1) and disorders: An emerging pharmacotherapeutic target What to know about how
Description
Many people taking Ozempic (a semaglutide) have suffered from severe gastrointestinal complications that they say they were not properly warned about
They have since been embraced for their effectiveness in promoting weight loss
Why Personalized Genetic Testing Matters for GLP-1 Response Thyroid disease and weight regulation both involve overlapping metabolic pathways controlled by multiple genes
2024 Jan 2 [cited 29 Jan 2025
